ISDA

Entry Detail

PDB ID:

4K4F

Keywords:

Title:

Co-crystal structure of TNKS1 with compound 18 [4-[(4S)-5,5-dimethyl-2-oxo-4-phenyl-1,3-oxazolidin-3-yl]-N-(quinolin-8-yl)benzamide]

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Escherichia coli

PDB Version:

Deposition Date:

2013-04-12

Release Date:

2013-06-05

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.90 Å

R-Value Free:

0.29

R-Value Work:

0.28

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Tankyrase-1
Chain IDs:A, B
Chain Length:217
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:O95271 Pfam ID:PF00644 EC:2.4.2.30

Ligand Molecules

K4F

Primary Citation

Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors.

Bregman, H, Chakka, N, Guzman-Perez, A, Gunaydin, H, Gu, Y, Huang, X, Berry, V, Liu, J, Teffera, Y, Huang, L, Egge, B, Mullady, E.L, Schneider, S, Andrews, P.S, Mishra, A, Newcomb, J, Serafino, R, Strathdee, C.A, Turci, S.M, Wilson, C, Dimauro, E.F.Show

J.Med.Chem. 56 4320 4342 (2013)

PMID: 23701517 DOI: 10.1021/jm4000038

Abstact

Tankyrase (TNKS) is a poly-ADP-ribosylating protein (PARP) whose activity suppresses cellular axin protein levels and elevates β-catenin concentrations, resulting in increased oncogene expression. The inhibition of tankyrase (TNKS1 and 2) may reduce the levels of β-catenin-mediated transcription and inhibit tumorigenesis. Compound 1 is a previously described moderately potent tankyrase inhibitor that suffers from poor pharmacokinetic properties. Herein, we describe the utilization of structure-based design and molecular modeling toward novel, potent, and selective tankyrase inhibitors with improved pharmacokinetic properties (39, 40).

Legend

Protein

Chemical

Disease

Primary Citation of related structures